CHAPPIE THOMAS ALLEN,HUMPHREY JOHN MICHAEL,VERHOEST PATRICK ROBERT,YANG EDDIE,HELAL CHRISTOPHER JOHN
申请号：
NZ61337312
公开号：
NZ613373A
申请日:
2012.02.09
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
The present disclosure relates to Imidazo[5,1-f][1,2,4]Triazine compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a PDE2 mediated disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. Compounds of the disclosure include: 4-(azetidin-1-yl)-7-methyl-5-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]imidazo[5,1-f][1,2,4]triazine, 4-(azetidin-1-yl)-7-methyl-5-{ 1-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl} imidazo[5,1-f][1,2,4]triazine, 4-(azetidin-1-yl)-5-[5-(5-chloropyridin-2-yl)-1-methyl-1H-pyrazol-4-yl]-7-methylimidazo[5,1-f][1,2,4]triazine, N,7-dimethyl-5-{ 1-methyl-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl} imidazo[5,1-f][1,2,4]triazin-4-amine, And 4-(azetidin-1-yl)-7-methyl-5-{ 1-methyl-5-[5-(trifluoromethyl)pyridin-2-yl]-1H-pyrazol-4-yl} imidazo[5,1-f][1,2,4]triazine.
